Internet Stroke Center Home Stroke Education for Clinicians & Students
 

Patients & Families   Health Professionals   Clinical Trials   About   Home 


Search the ISC 
Search the Web
 Stroke Education
Section Home
Glossary of
Neurological Terms

 Stroke Management
Thrombolytic Case Management Series
CT Learning Tool
Evaluation & Diagnosis
Stroke Care for EMT's & Paramedics
Management of Oral Anticoagulant Therapy
 Brain Anatomy
Anatomy of the Brain
Blood Vessels of the Brain
Pathogenesis & Pathophysiology
 Brain Imaging
Neurology Image Library
CT & MRI Criteria for Infarction & Hemorrhage
Guide to Imaging Techniques
MRI Compared to CT
 Stroke Facts
Epidemiology of Stroke
Stroke Risk Factors
Types of Stroke


Part One: Warfarin Dosing Guidelines

Warfarin: Dosing & Monitoring

Start low

  • Initiate 5 mg daily*

  • Educate patient

 

Stabilize

  • Titrate to appropriate INR

  • Monitor INR frequently (daily then weekly)

 

Adjust as necessary

  • Monitor INR regularly (every 1–4 weeks) and adjust

* Elderly, frail, liver disease, malnourished:  2 mg/day


Notes:

This slide provides guidelines for safe and effective warfarin use. The dose of warfarin should be monitored daily until the INR is in the therapeutic range and then  less frequently when a stable dose-response relationship is achieved. Regardless of the degree of stability in warfarin dosing and INR value in the hospital, it is important to monitor the INR frequently post hospital discharge (i.e., at least 1–3 days after discharge) and to spread out the interval of monitoring thereafter depending on INR response. Monitoring is necessary in all patients, but can be reduced to four weekly intervals in the low risk (for bleeding) patient who shows a stable dose-response.

 

Back

Contents

Next

About this presentation:

The content of these pages is from a presentation called  "Management of Oral Anticoagulant Therapy: Principles & Practice," prepared by the American Heart Association's Post-Graduate Education Committee of the Council on Clinical Cardiology.  Supported by an educational grant from DuPont Pharmaceuticals.

Authors: Jack Ansell, M.D., Jack Hirsch, M.D., Nanette K. Wenger, M.D.

Data current as of October 1999.

Endorsed by the Anticoagulation Forum and the American Heart Association Council on Atherosclerosis, Thrombosis, and Vascular Biology.

The entire PowerPoint presentation is available from the American Heart Association.

 

 

This site is a non-profit, educational service of Washington University School of MedicineInternet Stroke Center at Washington University:
TOP | HOME | ABOUT | PRIVACY POLICY | CONTACT

Copyright © 1997 - 2007 Internet Stroke Center. All rights reserved.

The information in this web site is not a substitute for medical advice or treatment.
Consultation with your doctor or health care professional is recommended.